Britain and America have hammered out a important trade agreement that will preserve no levies on UK medicine products being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This move guarantees that tariffs on these vital goods will stay at zero for a period of the next three years.
This agreement comes after previous threats to dramatically increase tariffs on patented drug imports, with increases floated reaching 100%.
"This arrangement between the UK bolsters the global environment for new treatments and introduces much-needed equity to transatlantic medicine commerce," a statement noted.
Commercial Impact
Medicines constitute one of the the United Kingdom's largest exports to the US, which is easily the primary destination for major UK drugmakers.
Statistics indicate that in the one-year period leading up to the third quarter, the UK sold drugs worth over eleven billion pounds to the US. This amount made up nearly one-fifth of all goods exports in that timeframe.
"This guarantee protects employment, increases investment and facilitates the UK to emerge as a international leader for biotech and pharma," a government official commented.
Specific UK Commitments
The agreement includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise total health service expenditure on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be capped at 15%. Last year, refunds exceeded twenty percent.
Broader Context
This agreement takes place against a protracted dispute between the drug companies and the ministers over medicine costs and regulatory access.
These tensions were intensified by claims that US patients were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while major expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a proportion of its resources over the previous ten-year period.
